IGFBP3 Antibody (Rabbit mAb) [G15L3]

Catalog No.: F9208

    Application: Reactivity:
    • Lane 1: AsPC-1
    1/
    サイズ 価格(税別) 在庫状況
    JPY 15900 お問い合わせ
    JPY 38900 国内在庫なし(納期7~10日)
    JPY 58400 お問い合わせ

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp
    よく尋ねられる質問

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min,Recommended to use 0.22 μm PVDF 膜の使用をお勧めします。

    使用情報

    Dilution
    1:1000
    1:100
    1:200 - 1:800
    1:400 - 1:1600
    Application
    WB, IP, IHC, IF
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    19 kDa
    ポジティブコントロール Normal human pancreas; Normal human kidney; Human urothelial carcinoma; Human renal cell carcinoma; Human endometroid carcinoma; Human urothelial carcinoma; HCC1937 cells; OVCAR-4 cells; HCC1143 cells; AsPC-1 cells; A-498 cells
    ネガティブコントロール HT-29 cells

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.22 µm PVDF membrane is recommended )Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    IGFBP3 Antibody (Rabbit mAb) [G15L3] detects endogenous levels of total IGFBP3 protein.
    タンパク質の局在
    細胞核、細胞外環境
    Uniprot ID
    P17936
    Clone
    G15L3
    Synonym(s)
    acid stable subunit of the 140 K IGF complex; binding protein 29; binding protein 53; BP-53; IBP-3; IBP3; IGF-binding protein 3; IGFBP-3; IGFBP3; insulin like growth factor binding protein 3
    Background
    Insulin-like growth factor binding protein-3 (IGFBP3) represents the most abundant member of the six-member IGFBP family in human circulation, functioning primarily as the major carrier protein for insulin-like growth factors IGF-I and IGF-II within ternary complexes containing the acid-labile subunit, where it prolongs IGF half-life from minutes to over twelve hours while regulating IGF bioavailability through high-affinity sequestration. IGFBP3 comprises three structural domains—a highly conserved cysteine-rich N-terminal domain containing twelve cysteine residues forming six intradomain disulfide bridges, a non-conserved central linker domain, and a conserved cysteine-rich C-terminal domain with six cysteines forming three disulfide bridges—with both terminal domains contributing cooperatively to IGF binding through distinct contact residues that together generate nanomolar binding affinity. The protein undergoes post-translational modifications, including N-glycosylation at three asparagine residues (Asn89, Asn109, Asn172) contributing variable carbohydrate content, producing characteristic doublets detectable by Western blot, phosphorylation at multiple serine residues by casein kinase 2 and DNA-dependent protein kinase, altering glycosaminoglycan binding and IGF affinity, and proteolytic cleavage by matrix metalloproteinases and pregnancy-associated plasma protein-A2 reducing IGF binding affinity to release bioactive IGF for receptor activation. IGFBP3 regulates IGF-dependent cellular processes through multiple mechanisms—canonical inhibition of IGF1R signaling by sequestering IGF-I and IGF-II preventing receptor access, potentiation of IGF1R activation through interaction with cell-surface glycosaminoglycans and extracellular matrix proteins concentrating IGFs near receptors, and suppression of IGF1R signaling by activating protein phosphatase 2A following binding to transforming growth factor-β receptor type V (TGFβRV/LRP1), leading to dephosphorylation of Akt and Ras/MAPK pathway components. The protein executes extensive IGF-independent functions initiated at the cell surface through interactions with transmembrane protein 219 (TMEM219), TGFβRI, TGFβRII, and TGFβRV receptors—TMEM219 binding triggers caspase-8-dependent apoptosis and forms calcium/calmodulin-dependent complexes inducing autophagy, while TGFβRV ligation activates protein phosphatase 2A, downregulating Akt survival pathways. IGFBP3 possesses cell-penetrating peptide properties mediated by overlapping glycosaminoglycan-binding, nuclear localization signal, and metal-binding domains within the C-terminal region, enabling cellular uptake through clathrin-mediated endocytosis via transferrin receptor interaction, caveolae-mediated endocytosis involving caveolin-1, and fluid-phase pinocytosis, with heparan sulfate proteoglycans facilitating membrane association and internalization. Following internalization, IGFBP3 translocates to the nucleus through direct importin-β binding independent of importin-α adaptor protein in an ATP- and GTP-dependent manner, where the bipartite nuclear localization signal within the C-terminal domain directs nuclear accumulation regulated by polyubiquitination and proteasomal degradation. Nuclear IGFBP3 functions as a transcriptional regulator through interactions with class II nuclear hormone receptors, including retinoid X receptor-α and vitamin D receptor, modulating their transcriptional activity, binds to DNA-dependent protein kinase catalytic subunit, participating in non-homologous end-joining double-strand DNA repair pathways, and interacts with numerous transcription factors influencing gene expression programs controlling apoptosis, cell cycle progression, and metabolic homeostasis. IGFBP3 regulates autophagy through multiple mechanisms—hypoglycosylated IGFBP3 under glucose and oxygen deprivation binds glucose-regulated protein 78 (GRP78) inducing autophagic survival responses in nutrient-stressed breast cancer cells, TMEM219-calmodulin-calcium/calmodulin-dependent kinase II complex formation triggers autophagy in kidney epithelial cells, interleukin-13-induced autophagy in bronchial epithelial cells depends on IGFBP3, while in corneal epithelium IGFBP3 suppresses mitophagy maintaining mitochondrial function through regulation of BNIP3L/NIX mitophagy receptor expression with nuclear accumulation correlating with altered mitochondrial respiration and cristae morphology. The protein modulates sphingolipid metabolism by upregulating sphingosine kinase 1 activity, generating pro-survival sphingosine 1-phosphate while decreasing pro-apoptotic ceramide levels, potentiating ligand-dependent activation of both IGF1R and EGFR through sphingosine 1-phosphate receptor signaling with EGFR transactivating IGF1R independent of IGF binding. IGFBP3 exhibits context-dependent pro-apoptotic or anti-apoptotic functions—the protein induces apoptosis in prostate cancer cells through caspase-dependent mechanisms operating independently of IGF binding, secretion, or nuclear concentration, activates STAT-1 and inhibits Akt/IGF-1R survival pathways in breast cancer cells, promoting apoptosis, yet paradoxically high nuclear IGFBP3 in triple-negative breast cancer xenografts correlates negatively with cleaved caspase-3 and predicts shorter survival with tumor growth driven by IGFBP3-stimulated sphingosine kinase 1 and EGFR activation. IGFBP3 expression becomes regulated at transcriptional and post-translational levels with disruption implicated in multiple malignancies—reduced circulating IGFBP3 combined with elevated IGF-I correlates with increased breast, colon, lung, and prostate cancer risk, p53 tumor suppressor directly induces IGFBP3 transcription positioning it as a p53-regulated growth inhibitor, IGFBP3 levels decline in malignant cells relative to normal tissues, and elevated nuclear IGFBP3 in prostate cancer significantly predicts tumor recurrence while serving as both prognostic marker and potential therapeutic target.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください